Business
ASX 200 investors underexposed to this potential ‘great news event’ – Motley Fool Australia
If an effective vaccine against the coronavirus were uncovered this week, many ASX 200 investors would be poorly positioned to benefit.
The silver bullet to slay the coronavirus and return life to normal remains elusive. But that doesn’t mean it might not be here sooner than most S&P/ASX 200 Index (ASX: XJO) investors are pricing in.
The world’s top institutions and brightest minds are working around the clock, after all, with record amounts of private and government funding pouring in.
However, recent setbacks with some leading vaccine trials, alongside announcements that any new vaccines may only prove 50–60% effective, …
-
General23 hours agoConcerns over US AUKUS review dismissed by deputy PM
-
General21 hours agoAustralian man dead in Bali villa shooting incident, local police say
-
General21 hours agoSurfing the waves of nostalgia with Brian Wilson
-
Noosa News23 hours agoNRL live updates: Newcastle Knights vs Sydney Roosters, North Queensland Cowboys vs Dolphins